Therapy targeting tumor blood vessels ought to inhibit tumor growth. However, tumors become refractory to antiangiogenic drugs. Therefore, therapeutic solutions should be sought to address cellular resistance to antiangiogenic therapy. In this regard, reversal of the proangiogenic and immunosuppressive phenotype of cancer cells, and the shift of the tumor microenvironment towards more antiangiogenic and immune-stimulating phenotype may hold some promise. In our study, we sought to validate the effects of a combination therapy aimed at reducing tumor blood vessels, coupled with the abrogation of the immunosuppressive state. To achieve this, we developed an oral DNA vaccine against endoglin. This antigen was carried by an attenuated Salmonella Typhimurium and applied before or after tumor cell inoculation into immunocompetent mice. Our results show that this DNA vaccine effectively inhibited tumor growth, in both the prophylactic and therapeutic settings. It also activated both specific and nonspecific immune responses in immunized mice. Activated cytotoxic T-lymphocytes were directed specifically against endothelial and tumor cells overexpressing endoglin. The DNA vaccine inhibited angiogenesis but did not affect wound healing. In combination with interleukin-12-mediated gene therapy, or with cyclophosphamide administration, the DNA vaccine resulted in reduced microvessel density and lowered the level of T reg lymphocytes in the experimental tumors. This effectively inhibited tumor growth and prolonged survival of the treated animals. Polarization of tumor milieu, from proangiogenic and immunosuppressive, towards an immunostimulatory and antiangiogenic profile represents a promising avenue in anticancer therapy.
INTRODUCTION
Despite recent progress in diagnostics, cancer remains a major medical challenge. There are 10 million new cancer cases worldwide every year. WHO expects the incidence to rise to 15 million in 2020. 1 Therefore, novel prophylactic, diagnostic and therapeutic anticancer approaches are urgently needed. An important aspect in progression of multiple tumor types is the interplay between genetic alterations within cancer cells and their surrounding microenvironment. 2 To sustain continued growth beyond 1 --2 mm 3 , tumor mass becomes dependent on generation of a new vascular network, with the structural support in the form of extracellular matrix, and contribution of several growth factors released by the activated stromal cells. 1, 3 It was originally believed that an effective therapy targeting tumor blood vessels should arrest tumor growth, restrain metastasis and exert a lasting effect without mutational drug resistance that limits the efficacy of traditional anticancer agents. 4 In spite of these predictions, long-term use of antiangiogenic drugs often leads to therapeutic escape involving a variety of mechanisms dependent on the properties of blood vessels, cancer cells and regulatory milieu of bone marrow derived cellular infiltrates. 3, 5, 6 Use of single antiangiogenic agents is thus not sufficient. 3, 7 Moreover, inhibiting endothelial cells proliferation may not be effective against tumor vasculature formed through such processes as intussusception 8 or vasculogenic mimicry. 9 --11 In addition, antiangiogenic therapy leads to the so-called post-drug hypoxia within tumor mass.
It is this type of hypoxia that is mainly responsible for invasiveness of cancer cells and formation of metastases. 3,12 --14 Novel therapeutic solutions must, therefore, take into account or omit such resistance. Cellular infiltrates strongly affect tumor progression through formation of the proangiogenic and immunosuppressive microenvironment that enables cancer cells to escape from immune surveillance, 15 while certain proangiogenic factors (for example, vascular endothelial growth factor (VEGF), transforming growth factor-b (TGF-b)) may act as immunosuppressants. 15 --18 Thus, it is the complex microenvironmental polarization toward proangiogenic and immunosuppressive phenotype (tumor growth-stimulation) that may present the main therapeutic obstacle, and consequently it is of interest to explore the means of its global reversal. 15, 19 In this study, we tested the effects of a combined immunotherapy targeted in such a way as to simultaneously decrease the number of tumor blood vessels and alleviate tumor immunosuppression. We relied on the finding that tumor vascular endothelial cells express specific surface proteins, 2 including endoglin (CD105), which also acts as the co-receptor for TGF-b, known to possess immunomodulating activity. Immune response directed against such self antigens overexpressed in the tumor vasculature has already been contemplated. 20 Endoglin is a unique marker of activated vascular endothelial cells and its presence in solid tumor blood vasculature is, in some cases, of prognostic value. sarcoma and prostate cancer). 24, 25 As a carrier of the endoglinencoding gene, we used an attenuated strain of Salmonella Typhimurium SL7207. 26, 27 In our study, we used experimental murine tumor models (B16-F10 melanoma and Renca renal carcinoma), in which neoplastic cells express endoglin on their surface. The DNA vaccine was therefore directed also against cancer cells. The antiangiogenic and antitumor effects were achieved through an oral DNA vaccine carried by Salmonella Typhimurium to secondary lymphoid organs such as Peyer's patches (PPs). Immunotherapy with this vaccine breaks immune tolerance against self antigens and activates cytotoxic CD8 þ T lymphocytes to destroy tumor vascular endothelial cells, leading to inhibition of tumor growth. 28 While endoglin-directed antiangiogenic DNA vaccines have already been explored to some extent, 29, 30 we focused on antitumor aspect of this approach and reasoned that its effect could be markedly enhanced by combination with carefully selected immunomodulating agents. For instance, the immune response in such vaccine-based treatment combinations could be reinforced through inclusion of interleukin-12 (IL-12) 31 or cyclophosphamide (CTX). 32 IL-12 is a pleiotropic immunomodulatory cytokine inducing both nonspecific (NK, NK-T) as well as specific (CD4, CD8) immune responses, in addition to the appreciable nonimmune antiangiogenic activity. 33 --36 Additionally, IL-12 eliminates T reg lymphocytes from tumor microenvironment, effectively abrogating tumor immunosuppression. 36 Similarly, the chemotherapy with CTX lowers the level of T reg lymphocytes, restores proliferation of peripheral T lymphocytes and activates nonspecific responses. 32, 37, 38 Moreover, CTX possesses a direct antiangiogenic activity 39 achieved, at least in part, by eliminating circulating endothelial progenitor cells. 32 We report that anti-endoglin DNA vaccine exerts indeed an antitumor and antiangiogenic effect in a model of aggressive murine melanoma. We did not observe any obvious side effects and when this treatment was combined with IL-12 or CTX durable antitumor responses were obtained along with repolarization of the tumor stroma toward an antiangiogenic and more immunocompetent phenotype. In ca. 30% of mice treated with our DNA vaccine and IL-12-mediated gene therapy total tumor regression was seen. On the other hand, immunotherapy combined with chemotherapy (CTX) led to a long-term stabilization of tumor growth. We suggest that targeted immunomodulation may be the key to successful anticancer treatment with antiangiogenic DNA vaccines.
RESULTS

Salmonella Typhimurium transfers the therapeutic gene to PPs
The construct pcDNA3.1( þ )/mCD105 ( Figure 1a ) was transfected into COS7 cells and the presence of the corresponding protein in eukaryotic cells was confirmed by western blotting (Figure 1b) . Next, pcDNA3.1( þ )/mCD105 plasmid was transferred into Salmonella Typhimurium SL7207 strain using electroporation. (a) DNA fragment encoding murine endoglin (mCD105) was obtained by PCR. The reaction product was then inserted into pcDNA3.1( þ ) plasmid using XbaI and KpnI restriction sites. (b) Protein expression of mCD105 was detected by transfecting COS7 cells with the plasmid and performing western blotting with rat anti-murine CD105 antibody. (c) Plasmid-carrying S. Typhimurium bacteria (1 Â 10 8 per animal) were orally administered to C57Bl/6 mice. After 24 h, the animals were killed, PPs collected and frozen sections obtained. EGFP protein-containing cells were identified using fluorescence microscopy (magnification Â 20). Mouse PPs were stained with hematoxylin/eosin. (d) Expression levels of endoglin (CD105) was examined in B16-F10, Renca and C26 tumor cell lines. As a control, HECa10 endothelial cells were used. Cells were stained with rat PE-conjugated monoclonal antibody recognizing murine endoglin.
Positive SL7207/mCD105 clones were used as a DNA vaccine in prophylactic and therapeutic settings. In our initial experiments, we confirmed that the orally administered Salmonella Typhimurium SL7207 strain, used by us as a delivery vehicle, effectively reached secondary lymphoid organs such as PPs in the small intestine.
In order to demonstrate the transfer of a eukaryotic gene to PPs, we used a reference gene (EGFP (enhanced green fluorescent protein)). In accordance with our assumptions, in vitro studies confirmed first Salmonella Typhimurium SL7207-mediated transfer of the eukaryotic gene (EGFP) into murine macrophages (data not shown). Next, in vivo studies (EGFP fluorescence) confirmed that the bacteria reached PPs and transferred the gene, which was subsequently expressed by the host cells (Figure 1c) .
Immunization of mice with DNA vaccine inhibits tumor growth in both prophylactic and therapeutic approach Antitumor properties of the oral endoglin-based DNA vaccine were investigated using two experimental murine tumor models (B16-F10 murine melanoma and Renca renal carcinoma) in which endoglin is overexpressed by cancer cells (Figure 1d) . First, in a prophylactic setting, DNA vaccine was administered orally three times before inoculating mice with either type of cancer cells (B16-F10 or Renca) (Materials and Methods for details). A significant inhibition of tumor growth was observed in case of both B16-F10 ( Figure 2a ) and Renca ( Figure 2c ) tumors, as compared with control (bacteria carrying plasmid without insert).
Induction of immune response was tested in a therapeutic setting (Materials and Methods for details). In brief, mice pre-inoculated with B16-F10 melanoma cells were administered the oral DNA vaccine and tumor growth inhibition was observed in the treated mice (Figure 2d ).
Oral DNA vaccine inhibits formation of experimental metastases Immunization of mice with SL7207/mCD105 bacteria (DNA vaccine) led to a significant inhibition in the formation of experimental B16-F10 melanoma metastases. Their number in the lungs of immunized mice decreased fourfold compared with mice receiving bacteria with empty plasmid (Figure 2c ). This suggests that the DNA vaccine indeed acts against both endothelial and B16-F10 melanoma cells.
Endoglin-based DNA vaccine activates T lymphocytes and dendritic cells The notable antitumor efficacy of the endoglin-directed vaccine suggests the existence of corresponding immune responses. In fact, we observed significantly elevated levels of activated immune cells in immunized mice, as compared with mice administered bacteria carrying the control plasmid. The number of cells bearing T lymphocyte markers (CD28, CD25 and CD69; Figure 3a) , and dendritic cells with co-stimulating molecules (CD80 and CD86; Figure 3b DNA vaccine induces endoglin-specific cytotoxicity In order to verify specificity of the immune response induced by the studied endoglin-directed DNA vaccine, we examined cytotoxicity of CTLs (cytotoxic T-lymphocytes) activated by this vaccine. To this purpose, we used B16-F10 melanoma and HECa10 endothelial cells (both overexpressing endoglin), as well as C26 colorectal carcinoma cells devoid of endoglin (Figure 1d ). Cells expressing endoglin (Figures 6a and b) were much more sensitive to CTLs than controls (Figure 6c ). DNA vaccine-induced CTLs were more active towards cells expressing endoglin, as compared with CTLs induced by empty plasmid-carrying bacteria. There were no differences in terms of cytotoxicity of CTLs against C26 cells devoid of endoglin (that is, between CTLs induced by DNA vaccine and by control vector). These data show an effective induction of the immune response directed against cells overexpressing endoglin. The response was directed against both endothelial and cancer cells.
Endoglin-based DNA vaccine inhibits angiogenesis in vivo Cytotoxicity tests have corroborated the finding that the induced immune response is directed against endothelial cells carrying endoglin on their surface. This glycoprotein is a marker of active proliferating endothelial cells participating in the formation of new blood vessels. We thus wanted to investigate whether the examined DNA vaccine affects inhibition of angiogenesis. To this purpose, we used a Matrigel test and fluorescein isothiocyanate (FITC)-labeled Isolectin B4 for staining of endothelium. Macroscopically, sizeable differences were visible in vascularization of Matrigel plugs. Endoglin-directed DNA vaccine inhibits neovascularization in immunized mice, as compared with mice receiving empty plasmid-carrying bacteria. The level of fluorescein in supernatants from Matrigel lysates was more than twofold lower for mice immunized with endoglin-based DNA vaccine, as compared with Matrigel lysates from controls ( Figure 7 ).
Combination of DNA vaccine and IL-12 gene therapy effectively inhibits tumor growth, decreases the number of blood vessels and the level of tumor T reg lymphocytes As mentioned earlier, we reasoned that the therapeutic effect of the oral endoglin-based DNA vaccine could be enhanced upon combination with intratumoral administration of antiangiogenic immunomodulators, such as IL-12. 31 This was found to be the case, as the intratumoral delivery of the IL-12-encoding plasmid resulted in a marked extension of antitumor effects associated with the DNA vaccine (Figures 8a and b) . Following complete tumor regression, B30% of mice treated with the combined regimen showed no signs of tumor re-growth. Mice treated with either monotherapy also exhibited tumor growth delay, but their survival was shorter than that of the mice treated with the combined approach (data not shown). Sections of tumors obtained from mice treated with combined therapy (DNA vaccine þ IL-12) showed significant numbers of necrotic areas and contained infiltrates of immune system cells ( Figure 8b ).
Immunohistochemical analyses demonstrated decreased numbers of blood vessels in tumor specimens obtained from mice treated with oral DNA vaccine combined with IL-12-mediated gene therapy (Figure 8c ) as compared with controls. Combination therapy involving oral DNA vaccine and IL-12 gene therapy, as well as monotherapies, markedly decreased the level of tumor T reg lymphocytes in the treated animals, as compared with controls.
This clearly underscores the benefit of a combined therapeutic approach in diminishing immunosuppression in tumor microenvironment ( Figure 8d ).
Oral vaccine therapy combined with CTX effectively inhibits tumor growth, decreases the number of blood vessels and the level of tumor T reg lymphocytes The oral vaccine was also tested in combination with intraperitoneal administration of CTX. This chemotherapeutic shows antiangiogenic effect under certain conditions, 39 and it also abrogates immunosuppression. 38 Considerable inhibition of B16-F10 murine melanoma tumor growth (Figures 9a and b) was observed in the mice receiving combined therapy (DNA vaccine and CTX), as compared with controls (receiving either monotherapy or phosphate-buffered saline (PBS À )). Combination of immunotherapy and chemotherapy did not affect body mass in any significant way (data not shown). As a result of this combination, a long-term stabilization of tumor growth was obtained, but never a complete regression, such as in the case of Compared with controls, combination of the oral DNA vaccine with CTX-mediated chemotherapy decreased the number of blood vessels, as well as markedly decreased the level of T reg lymphocytes found in tumor specimens obtained from mice treated with the vaccine and CTX (Figure 9c ). This underscores the benefits of combination therapies in abrogating immunosuppression in tumor microenvironment (Figure 9d ).
Endoglin-based DNA vaccine does not affect the rate of wound healing We confirmed the antitumor potential of the tested oral DNA vaccine, expressed as its ability to suppress neovascularization and to decrease the number of tumor blood vessels in mice treated with vaccine alone or in combination with immunomodulatory agents (Figures 7 and 9 ). This led us to examine whether the oral DNA vaccine is safe and whether it does affect other physiological forms of angiogenesis, such as wound healing.
The tests showed that oral administration of Salmonella Typhimurium carrying endoglin-encoding gene does not impede regeneration of damaged tissue (data not shown). Furthermore, the vaccine did not affect body mass of the tested animals nor their normal behavior (data not shown).
DISCUSSION
Solid tumors larger than 1 --2 mm 3 require formation of their own blood vascular network in order to sustain continued growth. 1, 3 Thus, treatment targeting tumor blood vessels should inhibit tumor progression. 4 Therapy attempts with antiangiogenic drugs, such as bevacizumab (avastin), sorafenib or sunitinib, have not been overly successful 5 in the past; protracted use of antiangiogenic drugs elicits therapeutic resistance. 3, 5, 6 Novel approaches to anticancer treatment should explore the issue of drug resistance shown by endothelial (and/or tumor) cells. One possible therapeutic solution might be tumor immunotherapy directed against antigens expressed on the surface of þ and CD8 þ lymphocytes was examined. Cells were stained with FITC-CD4 or FITC-CD8a and then fixed, permeabilized and stained with PE-IL-2, PE-IFN-g or PE-TNF-a. Higher levels of expressed cytokines were found. Statistical differences when compared with control vector group were *Po0.005 (a); **P ¼ 0.3 (b), ***Po0.05 (c). Figure 6 . Induction of endoglin-specific immune response (CTLs) by oral DNA vaccine. C57Bl/6 mice (n ¼ 3) were immunized and then challenged with B16-F10 cells (Materials and Methods). After 10 days, splenocytes were isolated, re-stimulated (Materials and Methods) and their cytotoxic activity analyzed by XTT test at various effector cell-to-target cell ratios. Murine endothelial cell line (HECa10), endoglinexpressing tumor cell line (B16-F10) and C26 cell line (negative control) were used as targets. Activated CTLs showed cytotoxicity only towards cells expressing CD105 on their surface. Statistical differences when compared with control vector group were *Po0.025 (a); *Po0.0005, **Po0.0015 (b). There were no differences in terms of cytotoxicity of CTLs against C26 devoid of endoglin (c).
endothelial cells that co-form tumor blood vasculature. 28, 40 Such therapy breaks immune tolerance against own antigen, elicits the immune system to recognize endothelial cells as foreign and induces immune reaction (mainly cytotoxic CD8 þ T lymphocytes) directed against these cells. 27, 28, 41, 42 In consequence, elimination of endothelial cells should lead to arrest of tumor growth, whereas long-term immune memory might prevent tumor relapse. 20, 28 Immunotherapy directed against tumor vessel endothelial cells offers several advantages: 40 first, these cells are more easily accessible to the immune system effectors, compared with neoplastic cells localized at greater distance from blood capillaries; second, destruction of a single endothelial cell can inhibit division of 4100 neoplastic cells; third, tumor vessel endothelial cells are more efficiently targeted by CD8 þ -mediated immune response compared with neoplastic cells that show lower MHC I (Major Histocompatibility Complex I) expression levels.
Tumor progression is affected to a substantial degree by various cells forming tumor microenvironment since they participate in de novo formation of tumor vasculature and they play a major role in establishing an immunosuppressive milieu that enables cancer cells' escape from immune surveillance. 15 Certain proangiogenic factors are also immunosuppressive agents (for example, VEGF, TGF-b). 15 --18 Thus, the issues of cellular resistance and long-term inhibition of tumor growth might be addressed with a therapeutic strategy that brings about polarization of a proangiogenic and immunosuppressive phenotype towards antiangiogenic and immunostimulating one. 15, 19 We sought to verify the effectiveness of a combined therapeutic approach that complements targeted destruction of tumor blood vasculature with induction of immune response, in order to restore tumor immune surveillance. We exploited the finding that tumor vascular endothelial cells express specific surface proteins, which can be useful as therapeutic targets.
2 Endoglin (CD105) is an antigen known to be highly specific for active tumor endothelial cells. 21 --23 In this study, we employed attenuated Salmonella Typhimurium SL7207 (aroA À ) bacterial strain 26 as a carrier of therapeutic plasmid construct encoding endoglin. Bacteria carrying endoglin-expressing plasmid were orally administered to mice (the latter either pre-or post-inoculated with cancer cells).
According to Darji et al. 27 , even a single dose (in the range of 10 8 c.f.u. per mouse) elicits a major cytotoxic response. The reaction is strongest during the fifth week post-immunization and then slowly declines. Orally administered Salmonella Typhimurium, used as a delivery vehicle, targets a therapeutic gene to secondary lymphoid organs such as PPs in the small intestine. Attenuated bacteria are phagocytosed by macrophages and dendritic cells. 27, 43 During subsequent transport of these cells into the spleen, the bacteria perish (mutation aroA À inhibits synthesis of aromatic amino acids) 26, 44 and release plasmid DNA carrying the therapeutic gene which is subsequently expressed. Proteolysis liberates peptides, which are presented to T lymphocytes mainly by MHC I molecules. 28 Such oral DNA vaccine has thus the ability to elicit immune response against own antigen and leads to destruction of endothelial cells lining tumor blood vessels and to tumor growth arrest. 28 We indeed observed inhibition of tumor growth in mice immunized with the oral endoglin-based DNA vaccine tested. Also, the number of experimental B16-F10 metastases found in immunized mice was decreased. Immunization led to the activation of immune system, seen as increased expression of important T lymphocyte markers (CD28, CD25 and CD69), and co-stimulating molecules (CD80 and CD86) on dendritic cells, as well as intracellular cytokines (IL-2, IFN-g and TNF-a) in T lymphocytes. In tumors from immunized mice, we detected increased infiltration of CD4 þ and CD8 þ T lymphocytes and NK cells. These results point clearly to a link between antitumor activity of our oral DNA vaccine and activation of the immune system response. The immune response (CTLs) induced by DNA vaccine was specifically directed against endoglin present on both endothelial and cancer cells. The vaccine markedly inhibited angiogenesis in immunized mice. Thus, inhibited growth of primary tumors and metastases in immunized mice was caused by suppression in tumor-associated angiogenesis and induction of endoglin-specific CTLs.
Previous attempts to stimulate the immune system against endoglin included a xenogenic protein 45, 46 and monoclonal antibodies. 47, 48 Our DNA vaccine offers several benefits: it stimulates a long-term immune response, is specific and safe and can be administered orally. 20 The likelihood of side effects of this therapy is rather small, since it is limited to proliferating endothelial cells, 2 or, as in our study, also to cancer cells overexpressing endoglin. Low cost, noninvasive way of administering, ease of preparation and storage, as well as efficient transfer of a therapeutic gene to the target site, all contribute to the usefulness of bacteria as carriers of therapeutic constructs. 49 Salmonella Typhimurium not only can harbor eukaryotic expression vectors, 28, 50 but it can also play the role of a natural adjuvant. 43 The bacteria trigger the release of TNF-a, IFN-g, IL-12 and other proinflammatory mediators. These agents enhance early nonspecific immune response and the developed inflammatory condition induces maturation of dendritic cells and antigen presentation. 43 This is mediated by CpG bacterial motifs. 51, 52 In addition, direct delivery of an antigen to peripheral lymphatic tissue by a bacterial carrier causes immunogenicity of such antigen to be increased 100-to 1000-fold, thereby inducing a strong and biologically active cytotoxic T lymphocyte response. 53 Figure 7. Suppression of neovascularization by endoglin-based oral DNA vaccine. C57Bl/6 mice (n ¼ 7) were immunized (Materials and Methods). Ten days after last immunization, Matrigel was implanted into mice. Six days later, FITC-labeled Isolectin B4 for staining of endothelium was used (Materials and Methods). Significantly lower fluorescence levels were detected in supernatants from Matrigel lysates. Statistical difference when compared with control vector group was *Po0.0004.
Optimum exploitation of antiangiogenic therapeutic approach requires involvement of several pathways engaged in angiogenesis. 54 So far, endoglin-directed vaccines were thought to affect only tumor endothelial cells. 28, 40, 45 Some data, however, suggest the presence of this transmembrane protein also on neoplastic cells.
55 CD105 inhibits migration and motility of prostate cancer cells. 25, 56 Overexpression of endoglin in squamous esophageal cancer, as well as breast cancer, decreases invasiveness and tumorigenicity of neoplastic cells. 57, 58 On the other hand, in melanoma or Ewing sarcoma, CD105 strongly stimulates tumor progression. 24 The level of endoglin expression in these two types of cancer correlates with the ability of tumor cells to form vessellike structures (vasculogenic mimicry). 59 CD105 protein regulates expression of integrin b3 and osteopontin, both required for vasculogenic mimicry. 24 Elimination of tumor cells featuring endoglin on their surface may stimulate aggressiveness (prostate cancer) or inhibit progression (melanoma). This is why DNA vaccine directed against endoglin could be used only in certain types of cancers.
Use of DNA vaccine directed against endoglin allows to circumvent several antiangiogenic drug resistance mechanisms. It is directed against both endothelial and neoplastic cells. Double targeting allows inhibition of angiogenesis and eradication of neoplastic cells, and might prove sufficient to arrest growth of certain types of tumors. One of the key advantages provided by endoglin is its much stronger expression in actively proliferating endothelial cells (43 Â 10 6 copies per cell), compared with other angiogenesis-related proteins, that is, VEGFRs (o0.2 Â 10 6 copies per cell). 60 The majority of antiangiogenic drugs acts only on proliferating endothelial cells that participate in angiogenesis. Endoglin present on the surface of activated endothelial cells and transdifferentiated tumor cells also contributes to vasculogenic mimicry. In human neuroblastoma tumors, up to 70% endothelial cells show both expression of CD105 and amplification of MYCN oncogene. 61 By destroying cells featuring endoglin (endothelial cells and transdifferentiated neoplastic cells), vasculogenic mimicry can be inhibited. Another drug resistance factor, hypoxia, stimulates secretion of proangiogenic factors and tumor progression. 62, 63 Hypoxia induces Percentage of Foxp3 þ CD25 high þ regulatory lymphocytes (subpopulation of CD4 þ lymphocytes) was determined from lymphocyte population gate. Considerably decreased amounts of tumor T reg lymphocytes were found for both regimens of combined therapies. Statistical differences (ANOVA) when compared with control group were *Po0.0004 (d).
elevated expression of CD105 in vascular endothelial cells. 22 CD105 acts independently of TGF-b counteracting apoptosis in endothelial cells subjected to hypoxic conditions. Thus, elimination of endoglin leads to enhanced cell apoptosis under such conditions. 64 In order to further enhance therapeutic benefits of our oral DNA vaccine, we tested it in combination with IL-12-mediated gene therapy or with chemotherapy (CTX). IL-12 is a pleiotropic cytokine known to activate immune response. 33 --36 The benefits of IL-12-mediated gene therapy include local production of this proinflammatory cytokine within the tumor. 35 Intratumoral administration of the therapeutic construct leads to its increased concentration at the site of endothelial cells' proliferation and this markedly enhances the antiangiogenic and antitumor effect. 65 CTX, besides destroying neoplastic cells, is an immunomodulatory agent. 36 CTX activates a nonspecific response, restores proliferation of peripheral T lymphocytes as well as significantly decreases the number of regulatory T lymphocytes. 37, 38 Accumulation of T reg in tumors shifts the balance of tumor microenvironmental equilibrium (involving regulatory T lymphocytes and effector cells) in the direction of immunosuppression. 66, 67 Abrogation of this immunosuppression can bring about a therapeutic effect seen as tumor growth arrest. 15 Suitable combinations of our DNA vaccine with IL-12 or CTX brought about long-term stabilization of tumor growth and, in some cases, complete regression.
The investigated DNA vaccine suppressed neovascularization and decreased the number of tumor blood vessels but it did not affect other physiological forms of angiogenesis (wound healing). Neither did it affect body mass nor cause behavioral changes in the experimental animals. Side effects were not observed with other vaccines directed against angiogenesis-participating factors (such as VEGFA, basic fibroblast growth factor or TEM8). 40 To conclude, the oral DNA vaccine developed by us is a variant of anticancer therapies aimed at eliminating tumor blood vessels and neoplastic cells. Suitable combinations of this DNA vaccine with antiangiogenic and immunomodulatory agents, such as IL-12 or CTX, caused polarization of tumor microenvironmental cells towards antiangiogenic, immunosuppression-abrogating phenotype, long-term stabilization of tumor growth and even complete tumor eradication. The therapeutic strategy combining antiangiogenic therapy with immunotherapy proved to be an effective and promising therapeutic approach. regulatory lymphocytes (subpopulation of CD4 þ lymphocytes) was determined from lymphocyte population gate. Considerably decreased amounts of tumor T reg lymphocytes were found for both regimens of combined therapies. Statistical difference (ANOVA) when compared with control group was **Po0.03 (d).
MATERIALS AND METHODS
Animals, bacterial strains, plasmids and cell lines
Mice (6-to 8-week-old CB7Bl/6 and BALB/c females) were bred in house. The experimental protocol was approved by Local Ethics Commission (Medical University of Silesia, Katowice, Poland). Salmonella Typhimurium LB5000 bacterial strain (r À m þ ) was obtained from Professor I Gentschev (University of Wü rzburg, Germany). The attenuated S. Typhimurium SL7207 (aroA À ) attenuated strain was kindly provided by Professor CA Guzmán (German Research Center of Biotechnology, Braunschweig, Germany). Both strains were cultured in LB broth supplemented with 100 mg ml --1 of ampicillin and with a mixture of amino acids, when required. Plasmid pBCMGSNeo carrying a gene encoding murine IL-12 was obtained from Professor H Yamamoto (Osaka University, Japan). Plasmid preparations were isolated using QIAGEN-Endo Free Giga Kit (Qiagen GmbH, Hilden, Germany). HECa10 (murine endothelial cells), J774.2 (mouse BALB/c monocyte macrophage cells), B16-F10 (murine melanoma), C26 (murine colon carcinoma), Renca (murine renal carcinoma) and COS7 (African green monkey SV-40-transferred kidney fibroblast cells) cell lines (ATCC, Manassas, VA, USA) were maintained using RPMI 1640 medium supplemented with 10% fetal bovine serum. COS7/mCD105 transfected cells were grown using medium containing 1 mg ml --1 G-418 (Sigma Aldrich, St Louis, MO, USA). Cell cultures were maintained in standard conditions (37 1C, 5% CO 2 , 95% humidity).
Vector construction and western blotting
The endoglin-encoding cDNA sequence was obtained by PCR. As a template, cDNA form murine salivary gland was used (Invitrogen, Carlsbad, CA, USA). Two oligonucleotides were used as starters: 5 0 -AAAAGGTACC ATGGACCGTGGCGTGC-3 0 and 5 0 -AAAATCTAGACTACGCCATGCTGCTGGT G-3 0 . The PCR product was cloned into pcDNA3.1( þ ) plasmid vector (Invitrogen) using KpnI and XbaI restriction sites under the control of the cytomegalovirus promoter. Recombinant plasmid pcDNA3.1( þ )/CD105 was then confirmed by sequencing to be identical to those in GeneBank (GI: BC029080). Expression of mCD105-encoding gene was determined by western blotting in cell lysates. The recombinant pcDNA3.1( þ )/mCD105 plasmid and pcDNA3.1( þ ) control plasmid were transfected into COS7 cells using FuGENE transfection reagent (Roche, Basel, Switzerland). Transfected cells were cultured under selective conditions (1 mg ml --1 G-418). To identify endoglin protein, a rat monoclonal antibody recognizing murine endoglin was used (R&D Systems, Minneapolis, MN, USA) and goat biotinylated antibody directed against rat IgG (R&D Systems).
DNA vaccine construct pcDNA3.1( þ )/mCD105 plasmid with inserted endoglin-coding sequence (1 mg) and pcDNA3.1( þ ) control plasmid (1 mg) were transferred into freshly preparated bacteria Salmonella Typhimurium LB5000 (3 Â 10 8 ) by electroporation (500 V, 1 impulse, 17 ms) using ECM 830 apparatus (BTX Harvard Apparatus, Holliston, MA, USA). Plasmid DNA isolated from single colonies obtained using selection plates was transferred by electroporation into attenuated Salmonella Typhimurium SL7207 strain (3 Â 10 8 ). Resistant colonies harboring the vaccine vectors were used in subsequent experiments.
In vitro and in vivo gene transfer Plasmid pcDNA3.1( þ )/EGFP (Clontech, Mountain View, CA, USA) was electroporated into Salmonella Typhimurium SL7207 bacteria. For in vitro experiment, J774.2 cells (2 Â 10 5 per well) were seeded into a 24-well plate. After a 24-h incubation, Salmonella Typhimurium bacteria carrying EGFP gene were added. Gentamycin was further added after 30 min incubation, followed by tetracycline (after 4 h). 68 Cells containing EGFP protein were examined at three time points (24, 48 and 72 h) using fluorescence microscopy (magnification Â 40). For in vivo experiment, mice were orally administered SL7207 bacteria containing the plasmid (1 Â 10 8 per 100 ml PBS À ). After 24 h, mice were killed and PPs were excised. 44, 69 Cryostat sections (10 mm thick) were then obtained. In order to identify cells showing green fluorescence (that is, those containing EGFP), the sections were viewed using fluorescence microscope (magnification Â 20).
Oral immunization, tumor cell challenge, treatment with immunomodulatory factors
In prophylactic experiments (induction of immune response before inoculation with cancer cells), mice were immunized by oral gavage (repeated three times at 1-week intervals), of SL7207/mCD105 bacteria (1 Â 10 8 per 100 ml PBS À ). 20, 29 Five minutes before administration, mice were given 100 ml 10% NaHCO 3 in order to neutralize gastric acid. In the fourth week, mice were challenged (subcutaneously or intravenously) with B16-F10 cells (1 Â 10 5 per 100 ml PBS À ) or Renca cells (5 Â 10 5 per 100 ml PBS À ). On day 23 of the experiment, the mice were killed, lungs were excised and fixed in Bouin's solution and the number of experimental metastases in lungs was determined. In therapeutic experiments, 1 day after inoculating mice with B16-F10 melanoma cells (1 Â 10 5 per 100 ml PBS À ), oral administration of the SL7207/mCD105 DNA vaccine (1 Â 10 8 per 100 ml PBS À ) was initiated. Bacteria were administered three times, 1 week apart. 31 Five minutes before each administration, mice were given 100 ml 10% NaHCO 3 . Additionally in combined therapy, on days 9, 11 and 13 following inoculation with cancer cells, pBCMGSNeo/mIL-12 plasmid was injected directly into tumors (20 mg DNA per 100 ml PBS À ).
31 CTX (Endoxan, Baxter, Halle, Germany) was administered intraperitoneally (170 mg kg --1 body mass) 39 on days 7, 13 and 19 following tumor cell challenge. Growing tumors were measured with calipers and tumor volumes were determined using the formula: volume ¼ width 2 Â length Â 0.52.
Immunohistochemistry
Paraffin sections (5 mm) were prepared from tumor material collected and fixed on the 20th or 24th day of the experiments testing one of the combined therapies (DNA vaccine þ IL-12 or DNA vaccine þ CTX, respectively). The sections were then stained immunohistochemically: following incubation at 4 1C for 19 h with rabbit anti-CD31 polyclonal primary antibody (Abcam, Cambridge, UK), the sections were incubated at room temperature for 30 min with secondary antibody labeled with horseradish peroxidase. Finally, the sections were incubated with Vector VIP peroxidase substrate (Vector Laboratories, Burlingame, CA, USA) and, additionally, with hematoxylin.
Flow cytometric analysis
Endoglin expression was identified in a murine endothelial cell line HECa10 (positive control) and in three tumor cell lines (B16-F10, Renca and C26). The expression level was determined using PE-CD105 antibody and PE-isotype control. Spleen-derived single-cell suspensions from immunized mice were isolated after 2 --3 weeks following inoculation with cancer cells. The preparations were checked for the level of activated T lymphocytes 29 using the following antibodies: PE-CD28 and FITC-CD8a (eBioscences, San Diego, CA, USA); PE-Cy7-CD25, PE-CD69 and FITC-CD3e (BD Pharmingen, San Diego, CA, USA). Also, the expression level of co-stimulating molecules on dendritic cells was checked using PE-CD80, PE-CD86 and FITC-CD11c antibodies (eBioscences). For intracellular staining of IFN-g, TNF-a i IL-2, splenocytes were stimulated with Leukocyte Activation Cocktail (BD Pharmingen) for 4 h. The following antibodies were used to identify cytokines: PE-IFN-g, PE-TNF-a, PE-IL-2, FITC-CD8a and FITC-CD4 (BD Pharmingen). Three weeks following inoculation of immunized mice with B16-F10 melanoma cells, tumor material was collected for flow cytometric analysis and single-cell suspension obtained using a digestion mix (0.5 mg ml --1 collagenase A, Sigma Aldrich; 0.2 mg ml --1 hyaluronidase type V, Sigma Aldrich; 0.02 mg ml --1 DNase I, Roche; per each 0.25 g of tumor tissue). Red blood cells were lysed using 0.15 M ammonium chloride solution. Dead cells were removed by centrifugation on Lympholyte-M gradients (Cedarlane, Ontario, Canada). 36 To identify the subpopulations of T lymphocytes, the following antibodies were used: PE-Cy7-CD3e, PE-CD4 and FITC-CD8a (BD Pharmingen). T reg lymphocytes were identified with FITC-CD4, APC-CD25 and PE-Foxp3 antibodies (eBiosciences). Finally, to identify the level of NK cells, an anti-mouse CD49b (pan-NK cells) antibody was used (eBioscences). In all flow cytometry analyses (BD FACSCanto, BD, Franklin Lakes, NJ, USA), gate dividing negative from positive cells was based on isotype antibody control probes.
Cytotoxicity assay
In all, 10 days after tumor cell challenge, splenocytes were isolated from immunized mice and co-cultured (37 1C/5% CO 2 ) with mitomycin C (80 mg per 10 7 cells; 70 Sigma Aldrich)-treated endoglin-expressing target cells (HECa10) using complete T-STIM culture medium (BD Biosciences, San Jose, CA, USA). Four days later, cytotoxicity of these splenocytes was assessed using In Vitro Toxicology Assay Kit (Sigma Aldrich), an XTT-based test against target cell lines: B16-F10, HECa10 cells (both overexpressing endoglin) and C26 cells (without endoglin; negative control).
Angiogenesis assay
Two weeks after last immunization, mice were injected subcutaneously, near the abdominal midline, with 500 ml of growth factor reduced Matrigel (BD Pharmingen) containing 0.4 mg ml --1 of recombinant mouse fibroblast growth factor-basic (R&D Systems). After 6 days, 200 ml (0.1 mg ml --1 ) of fluoresceinlabeled Griffonia simplicifolia lectin I, Isolectin B4 (Vector Laboratories) was injected into tail vein. Then, after 20 min, the mice were killed, Matrigel plugs were excised and homogenized in RIPA lysis buffer. 69, 70 The lysates (n ¼ 7) were centrifuged and fluorescein content in supernatants was determined by fluorimetry at 515 nm. In each case, background fluorescence was determined in noninjected control mice and subtracted.
Assessment of possible side effects
Four full-thickness circular excisional wounds (4 --5 mm diameter) per mouse were made 1 week after the last immunization and time elapsed until complete wound closure was measured. 20, 71 Animal behavior and changes in body mass of the treated and control mice were evaluated.
Statistical analysis
Tumor growth kinetics and statistical significance of differences between the experimental and control groups in immunological and immunohistochemical analyses were evaluated by ANOVA (analysis of variance). The comparisons between the two groups were analyzed by Student's t-test. P-values o0.05 were considered statistically significant.
